Condensed Consolidated Statement of Operations and Comprehensive Loss - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Biosecurity revenue:
Total revenue		$ 168,405	$ 44,097
Costs and operating expenses:
Research and development		322,720	59,585
General and administrative expenses		434,768	17,927
Total operating expenses		842,920	101,212
Loss from operations		(674,515)	(57,115)
Other income (expense):
Interest expense, net		(397)	(475)
Loss on equity method investments		(20,887)	(28,624)
Gain on investments		450	12,622
Change in fair value of warrant liabilities		85,035	0
Gain on deconsolidation of subsidiary		15,900	0
Other income (expense), net		1,637	(1,345)
Total other income (expense), net		81,738	(17,822)
Loss before income taxes		(592,777)	(74,937)
Income tax benefit		(184)	(159)
Net Loss		(592,593)	(74,778)
Net loss attributable to non-controlling interest		(2,088)	(1,209)
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders		$ (590,505)	$ (73,569)
Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders, basic and diluted	[1]	$ (0.37)	$ (0.06)
Weighted average common shares outstanding, basic and diluted	[1]	1,607,499,887	1,290,282,994
Comprehensive loss:
Net loss		$ (592,593)	$ (74,778)
Other comprehensive income (loss):
Foreign currency translation adjustments, net of taxes		(640)	0
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total		(640)	0
Comprehensive loss		(593,233)	(74,778)
Product [Member]
Biosecurity revenue:
Total revenue		13,947	5,775
Costs and operating expenses:
Cost of Biosecurity revenue		8,095	9,935
Service [Member]
Biosecurity revenue:
Total revenue		132,970	15,818
Costs and operating expenses:
Cost of Biosecurity revenue		77,337	13,765
Foundry Revenue [Member]
Biosecurity revenue:
Total revenue		$ 21,488	$ 22,504

[1] Amounts for the three months ended March 31, 2021 have been retroactively restated for the reverse recapitalization as described in Note 1.